XTL Biopharmaceuticals Ltd XTLB
XTL Biopharmaceuticals Ltd (Nasdaq: XTLB) is a CNS/neurology/psychiatry drug developer. Its lead program, Psyga Bio psilocybin-derived candidates (Phase 2a trials approved, not yet enrolling), is in Pre-clinical for Treatment-resistant depression, PTSD, anorexia, addiction and other CNS/mental health disorders. Its next catalyst on record is Psyga Bio pipeline: Commencement of at least three human clinical trials (milestone for earn-out shares) (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Psyga Bio pipeline — Commencement of at least three human clinical trials (milestone for earn-out shares) (H1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| hCDR1 (legacy XTL asset) | Systemic lupus erythematosus and Sjogren's syndrome; described as Phase II-ready, R&D spending reduced pending funding or partner (background 2021 prospectus) | protein/peptide | Phase 2 |
| Psyga Bio psilocybin and derivative programs | Seven approved Phase 2a human clinical trials across mental health, neurological, trauma, addiction and other CNS indications; patient enrollment expected to commence | small molecule | Pre-clinical |
| Ibogaine-based products (Psyga) | Psychiatric/addiction use; development contingent on a third-party partnership | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.